Effect of etoricoxib on IL-1βand TNF-αwith gouty arthritis
10.3969/j.issn.1005-1678.2016.12.018
- VernacularTitle:依托考昔对痛风性关节炎患者IL-1β、TNF-α的影响
- Author:
Lijian WANG
;
Weizuo ZHAO
;
Xiaochun ZHU
- Keywords:
etoricoxib;
gouty arthritis;
interleukin-1β;
tumor necrosis factor -α
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(12):69-71
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study effect of etoricoxib on IL-1βand TNF-αin patients with gouty arthritis.Methods 86 patients with gouty arthritis from July 2014 to July 2016 in our hospital were selected, all patients were divided into study group and control group according to the treatment method with 43 cases in each group.The patients in the control group were treated with diclofenac sodium, the patients in the study group were treated with etoricoxib.The clinical symptoms, clinical treatment effects, VAS score, serum IL-1β, TNF-αlevels and adverse reactions were observed and compared between the two groups.Results The VAS score, the joint swelling score and the mobility limitation score of the study group were decreased than before treatment and significantly lower than those of the control group, the difference was statistically significant (P<0.05).The effective rate of the study group (95.35%) was significantly higher than that of the control group (79.07%), the difference was statistically significant(P<0.05).The levels of IL-1βand TNF-αin the two groups were significantly lower than before treatment and the levels of IL-1βand TNF-αin the study groups were significantly lower than those in the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was lower than that in the control group, the difference was statistically significant(P<0.05).Conclusion The clinical efficacy of etoricoxib in treating patients with gouty arthritis is significant, which can effectively relieve the clinical symptoms, inhibit the expression of IL-1βand TNF-α, and the adverse reactions less.
